The diabetes vaccine Diamyd® to be featured in two oral presentations at the International Diabetes Federation Congress
Two abstracts, highlighting clinical results that showed improved glycemic control following treatment with Diamyd[®] (GAD-alum) as well as the design of the precision medicine Phase III trial DIAGNODE-3, have been elected for oral poster presentations at the International Diabetes Federation Congress (IDF) to be held as a digital event on December 6-11, 2021. The abstracts will be presented by Professor Johnny Ludvigsson, Linköping University, and Ulf Hannelius, CEO of Diamyd Medical.“It is a great honor and a testament to the importance of our work that the therapeutic diabetes vaccine